The Food and Drug Administration (FDA) and Department of Health and Human Services hold a public advisory committee meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee from 9:30 a.m. to 5:30 p.m. ET on May 9.
The committees discuss supplemental new drug application (sNDA) 017031/S-041, for OPILL (norgestrel) Tablet, 0.075 mg, submitted by Laboratoire HRA Pharma. OPILL is proposed for nonprescription use as a once-a-day oral contraceptive to prevent pregnancy.
